Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

NCT02658916 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
47
Enrollment
INDUSTRY
Sponsor class

Stopped 251PP301(NCT03068468) primary endpoint was not met;further development of Gosuranemab BIIB092 in progressive supranuclear palsy will not be pursued.

Conditions

Interventions

Sponsor

Biogen